Briacell Therapeutics Corp (BCTX)

$3.56 -0.07 (-1.93%)
Market Cap 31.58M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 96,200
Avg Vol 327,120
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 40%
Beta 1.10
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
BCTX20bMC
BCTX20bMC Sep. 14 at 11:00 PM
$BCTX moved 5%+ AH from 10 shares….when she rockets …it will be mind blowing. 🌋🌋🌋
0 · Reply
Firstvik
Firstvik Sep. 14 at 10:25 PM
$BCTX And the market goes mild! Dilution next up lol
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 7:33 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #Immunotherapy
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 6:55 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. #BCTX #CancerResearch #Immunotherapy
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 6:55 PM
$BCTX Just to remind everyone that after tomorrow they are allowed to dilute again, so don't be surprised if it happens.
1 · Reply
Merlintrader
Merlintrader Sep. 14 at 4:57 PM
BriaCell ($BCTX) Stock Hub: Seventh DSMB Recommendation to Continue Phase 3 https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:54 PM
BriaCell Therapeutics Corp. $BCTX is developing novel immunotherapies for patients with metastatic breast cancer. Its pivotal Phase 3 Bria-ABC study is evaluating Bria-IMT™ plus an immune checkpoint inhibitor. The seventh consecutive positive DSMB recommendation marks another milestone in the program. NEWS: https://bit.ly/46Ho2b3 #BCTX #Immunotherapy #BiotechStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:47 PM
BB's Stock Haven : Another key milestone for $BCTX: the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954881 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:44 PM
$BCTX BriaCell Therapeutics Corp. continues its Phase 3 Bria-ABC study under FDA Fast Track designation. The latest independent DSMB review recommends continuing the study without modifications. Clinical-stage biotech remains an area to watch. 🔬 NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #FDA #Stocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:41 PM
$BCTX: 7th consecutive positive - WINNERS CIRCLE https://investorshangout.com/post/view?id=6844429
0 · Reply
Latest News on BCTX
BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook

2026-09-14T12:52:23.000Z - 1 day ago

BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook

BriaCell announces DSMB recommendation to continue Bria-ABC study

2026-09-14T11:35:52.000Z - 1 day ago

BriaCell announces DSMB recommendation to continue Bria-ABC study

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400 - 1 day ago

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400 - 7 days ago

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics

2026-08-24T12:57:02.000Z - 22 days ago

BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

2026-08-24T11:35:06.000Z - 22 days ago

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

Mon, 24 Aug 2026 07:30:00 -0400 - 22 days ago

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

2026-08-05T13:46:04.000Z - 5 weeks ago

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T13:27:49.000Z - 2 months ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

2026-07-16T11:40:48.000Z - 2 months ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Thu, 16 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T13:32:56.000Z - 2 months ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

2026-07-15T12:10:22.000Z - 2 months ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Wed, 15 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 2 months ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 2 months ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 2 months ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 3 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 3 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 3 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 3 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 4 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 4 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 4 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 4 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 4 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 4 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 4 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 4 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 5 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 6 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 6 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 6 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:30 AM EDT - 6 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BCTX

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Mar 5, 2026, 4:04 PM EST - 6 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BCTX

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Feb 18, 2026, 5:30 PM EST - 6 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BCTX

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Jan 28, 2026, 7:30 AM EST - 7 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BCTX

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 27, 2026, 7:30 AM EST - 7 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BCTX

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 8 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BCTX

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 8 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BCTX

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 8 months ago

BriaCell Therapeutics trading resumes

BCTX

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 8 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BCTX

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 8 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

BCTX

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 9 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BCTX

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BCTX

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 9 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BCTX

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BCTX

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BCTX

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BCTX

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 10 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BCTX

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BCTX

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 10 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BCTX

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 10 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BCTX

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BCTX

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BCTX

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BCTX

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BCTX

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BCTX

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BCTX

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BCTX

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BCTX

BCTX20bMC
BCTX20bMC Sep. 14 at 11:00 PM
$BCTX moved 5%+ AH from 10 shares….when she rockets …it will be mind blowing. 🌋🌋🌋
0 · Reply
Firstvik
Firstvik Sep. 14 at 10:25 PM
$BCTX And the market goes mild! Dilution next up lol
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 7:33 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #Immunotherapy
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 6:55 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. #BCTX #CancerResearch #Immunotherapy
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 6:55 PM
$BCTX Just to remind everyone that after tomorrow they are allowed to dilute again, so don't be surprised if it happens.
1 · Reply
Merlintrader
Merlintrader Sep. 14 at 4:57 PM
BriaCell ($BCTX) Stock Hub: Seventh DSMB Recommendation to Continue Phase 3 https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:54 PM
BriaCell Therapeutics Corp. $BCTX is developing novel immunotherapies for patients with metastatic breast cancer. Its pivotal Phase 3 Bria-ABC study is evaluating Bria-IMT™ plus an immune checkpoint inhibitor. The seventh consecutive positive DSMB recommendation marks another milestone in the program. NEWS: https://bit.ly/46Ho2b3 #BCTX #Immunotherapy #BiotechStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:47 PM
BB's Stock Haven : Another key milestone for $BCTX: the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954881 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:44 PM
$BCTX BriaCell Therapeutics Corp. continues its Phase 3 Bria-ABC study under FDA Fast Track designation. The latest independent DSMB review recommends continuing the study without modifications. Clinical-stage biotech remains an area to watch. 🔬 NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #FDA #Stocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:41 PM
$BCTX: 7th consecutive positive - WINNERS CIRCLE https://investorshangout.com/post/view?id=6844429
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:25 PM
BB's Stock Haven : Another key milestone for $BCTX : the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177955240 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:58 PM
Positive safety update for $BCTX! BriaCell’s independent Data Safety Monitoring Board has issued its seventh consecutive recommendation to continue the pivotal Phase 3 study. No safety or other clinical concerns were raised in the latest review. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #HealthcareStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:38 PM
🚨 $BCTX NEWS ALERT 🚨 BriaCell Therapeutics Corp. announces its seventh consecutive positive DSMB recommendation for the pivotal Phase 3 Bria-ABC study in metastatic breast cancer. The independent board found no safety or other clinical concerns and recommended continuing without modifications. NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #CancerResearch #Stocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:24 PM
Whale Team : Independent DSMB recommends continuing $BCTX's pivotal Phase 3... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954938 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:16 PM
Another key milestone for $BCTX: the independent DSMB has again recommended continuing BriaCell's Phase 3 Bria-ABC study with no safety concerns identified. This marks the 7th consecutive positive DSMB review. #CancerResearch #Biotech NEWS: https://bit.ly/46Ho2b3 #BCTX
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:02 PM
BriaCell Therapeutics Corp ( $BCTX ): $BCTX: 7th consecutive positive DSMB rec... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954763 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 1:49 PM
$BCTX: 7th consecutive positive DSMB recommendation for the Phase 3 Bria-ABC study in metastatic breast cancer. The independent board reported no safety concerns and recommended the trial continue without modifications. #Biotech #BreastCancer NEWS: https://bit.ly/46Ho2b3
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 11:40 AM
$BCTX 7th continue as usual, let's go
0 · Reply
BABYLENNY
BABYLENNY Sep. 14 at 11:37 AM
$BCTX Here we go..its coming.
0 · Reply
JediGreen
JediGreen Sep. 14 at 11:37 AM
$BCTX
0 · Reply
JediGreen
JediGreen Sep. 14 at 11:36 AM
$BCTX Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study https://feeds.issuerdirect.com/news-release.html?newsid=5576870725019346&symbol=BCTX
0 · Reply
SmallCapVoice
SmallCapVoice Sep. 14 at 11:36 AM
$BCTX’s pivotal Phase 3 Bria-ABC study has received its 7th consecutive positive DSMB recommendation, with no safety concerns and no changes recommended. Another independent review supports continued progress in BriaCell’s metastatic breast cancer program. https://www.globenewswire.com/news-release/2026/09/14/3360977/0/en/data-safety-monitoring-board-dsmb-recommends-continuing-briacell-s-phase-3-metastatic-breast-cancer-study.html
0 · Reply